Cartesian Therapeutics, Inc. (RNAC)

23.20 -2.53 (-9.85%) At close: 04:00PM EDT

Cartesian Therapeutics, Inc.

704 Quince Orchard Road
Gaithersburg, MD 20878
United States
617 923 1400
https://www.cartesiantherapeutics.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 37

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Carsten Brunn Ph.D.	President, CEO & Director	4.67M	N/A	1972
Mr. Blaine T. Davis	Chief Financial Officer	2.49M	N/A	1975
Dr. Metin Kurtoglu M.D., Ph.D.	Chief Technology Officer	398.28k	N/A	1979
Dr. Chris Jewell Ph.D.	Chief Scientific Officer	296.85k	N/A	1982
Mr. Matthew Bartholomae J.D.	General Counsel & Secretary	N/A	N/A	N/A
Dr. Milos Miljkovic M.D., Ph.D.	Chief Medical Officer	N/A	N/A	1984
Dr. Emily English Ph.D.	SVP & Head of Manufacturing	N/A	N/A	1980
Mr. Yi Zhang Ph.D.	Senior Director of Technology	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.

Corporate governance

Cartesian Therapeutics, Inc.’s ISS governance QualityScore as of 1 May 2024 is 8. The pillar scores are Audit: 9; Board: 7; Shareholder rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.